Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cytokine Hemadsorption in Covid 19 Patients With Bacterial Sepsis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04920851
Recruitment Status : Recruiting
First Posted : June 10, 2021
Last Update Posted : June 10, 2021
Sponsor:
Information provided by (Responsible Party):
İLKE KÜPELİ, Biruni University

Brief Summary:
In this retrospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.

Condition or disease Intervention/treatment
INTERLEUKIN 6 Device: cytokine hemadsorption

Layout table for study information
Study Type : Observational
Estimated Enrollment : 23 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis
Estimated Study Start Date : June 10, 2021
Estimated Primary Completion Date : July 5, 2021
Estimated Study Completion Date : July 20, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Group/Cohort Intervention/treatment
Covid with sepsis
Covid patient with sepsis
Device: cytokine hemadsorption
to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.

covid without sepsis
Covid patient without sepsis
Device: cytokine hemadsorption
to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.




Primary Outcome Measures :
  1. interleukin 6 [ Time Frame: 1 month ]
    level of interleukin 6



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
23 COVID-19 patients were the available data of laboratory diagnosis of COVID-19 (a positive throat swab nucleic acid test or positive serum COVID-19 specific antibody test), and the criteria for patients with COVID-19 induced sepsis was detection of bacterial agent in blood or tracheal culture
Criteria

Inclusion Criteria:

  • COVID-19 patients were the available data of laboratory diagnosis of COVID-19 (a positive throat swab nucleic acid test or positive serum COVID-19 specific antibody test),
  • patients with COVID-19 induced sepsis was detection of bacterial agent in blood or tracheal culture

Exclusion Criteria:

  • below 18 aged
  • those who did not undergo hemoperfusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04920851


Contacts
Layout table for location contacts
Contact: ilke küpeli 05555485632 ilkeser2004@gmail.com

Locations
Layout table for location information
Turkey
Biruni University Recruiting
Istanbul, Küçükçekmece, Turkey, 34100
Contact: ilke küpeli    05555485632    ilkeser2004@gmail.com   
Sponsors and Collaborators
Derince Training and Research Hospital
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: İLKE KÜPELİ, ASSOC. PROF, Biruni University
ClinicalTrials.gov Identifier: NCT04920851    
Other Study ID Numbers: BIRUNI 1
First Posted: June 10, 2021    Key Record Dates
Last Update Posted: June 10, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes